ArticleQuantitative imaging in medicine and surgery2026
Prognostic value of ultrasound Breast Imaging Reporting and Data System for disease-free survival in early-stage breast cancer: a retrospective study (2011-2018).
Article in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Breast Imaging Reporting and Data System (BI-RADS) offers a standardized diagnostic risk stratification framework for assessing breast lesions. However, whether the imaging phenotype captured by the preoperative ultrasound (US) BI-RADS category is associated with long-term survival in early-stage breast cancer (BC) remains unclear. The aim of this study was to evaluate the prognostic value of the preoperative US BI-RADS category and to develop a nomogram integrating this imaging marker with clinicopathological factors to predict disease-free survival (DFS). Methods: We retrospectively analyzed 681 patients with early-stage BC (2011-2018). Survival outcomes across different US BI-RADS categories were compared using Kaplan-Meier curves and log-rank tests. Associations between candidate variables and survival outcomes were evaluated using univariate and multivariate Cox regression analyses. We developed a US-based nomogram with US BI-RADS category, lymph node metastasis (LNM), and Ki-67 to predict 5- and 10-year DFS. We also built a clinical model based on standard clinicopathological factors for comparison. We assessed both models using bootstrap-corrected concordance index (C-index) and area under the receiver operating characteristic (ROC) curve (AUC), and constructed calibration curves to compare predicted with observed DFS. Results: Patients with US BI-RADS categories 3-4B showed significantly superior DFS compared to those with categories 4C-5 (P=0.004). Multivariate Cox regression analysis identified US BI-RADS categories 4C-5 and Ki-67 index ≥20% as independent predictors of less favorable DFS. The US-based nomogram demonstrated good predictive performance, with a C-index of 0.701 [95% confidence interval (CI): 0.611-0.770] and well-fitted calibration curves. The 5- and 10-year time-dependent AUCs were 0.720 (95% CI: 0.624-0.801) and 0.647 (95% CI: 0.549-0.738), respectively. Compared with the clinical model, the US-based nomogram showed improved discrimination. Conclusions: We identified the preoperative US BI-RADS category as a promising prognostic imaging phenotype marker for early-stage BC. Based on this marker, we developed a nomogram that outperformed the clinical model based on traditional prognostic factors. However, these preliminary findings require validation in broader populations prior to clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.